Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$73.0M
50M shares
52-week range
$0.66 – $3.82
23% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
www.ibioinc.comNo one on the platform currently holds IBIO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 353,339 | $681.9K |
| Execution date | Ratio |
|---|---|
| 2023-11-29 | 1-for-20reverse |
| 2022-10-10 | 1-for-25reverse |
| 2018-06-11 | 1-for-10reverse |
No one on the platform has traded IBIO yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $85714 | -45.5% | $-0.31 | $-0.35–$-0.26 | — | 5 |
| 2028 | $125000 | +45.8% | $-0.40 | $-0.43–$-0.37 | — | 2 |
| 2029 | $250000 | +100.0% | $-0.68 | $-0.68–$-0.68 | — | 1 |
| 2030 | $500000 | +100.0% | $-0.95 | $-0.95–$-0.95 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-12 | $-0.06 | $-0.07 | -16.7% |
| 2026-02-10 | $-0.08 | $-0.09 | -12.5% |
| 2025-11-12 | $-0.07 | $-0.11 | -57.1% |
| 2025-09-05 | $-0.39 | $-0.31 | +20.5% |
| 2025-05-02 | $-0.39 | $-0.49 | -25.6% |
| 2025-02-10 | $-0.45 | $-0.48 | -6.7% |
| 2024-11-12 | $-0.48 | $-0.46 | +4.2% |
| 2024-09-25 | $-0.47 |
| $-0.91 |
| -93.6% |
| $11M |
| — |
| ITRMIterum Therapeutics plc | $0.03 | -10.98% | $2M | — |
| KLTOKlotho Neurosciences, Inc. | $0.38 | -7.10% | $20M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$IBIO Something is cooking. You know, they know, I know.
View on StockTwits ↗$IBIO I believe the addition of Dr Carr is a very significant event. Why would she jump ship from Lilly to go to what is essentially a start up? She has a tremendous amount of experience in this field and it is a coup to get someone of her caliber. Makes me think that Lilly is more than a passive observer in iBio’s progress. Perhaps they know they will be bringing Dr Carr back to Lilly in the near future. Time will tell, but I am feeling a distinct building of momentum
View on StockTwits ↗$TPST Will there be another day with gains of 4,000% or more here? $BNTX $IBIO $IBM
View on StockTwits ↗$IBIO https://womenstabloid.com/ibio-appoints-endocrinologist-molly-carr-as-chief-medical-officer/
View on StockTwits ↗$IBIO Sitting on major support if holds buy it up. $1.35 -$1.33 range should hold
View on StockTwits ↗$RNXT and technically all categories are showing growth... $UAA $IBIO
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.